DE69003015D1 - Behandlung von Störungen in der Postmenopause. - Google Patents

Behandlung von Störungen in der Postmenopause.

Info

Publication number
DE69003015D1
DE69003015D1 DE90111365A DE69003015A DE69003015D1 DE 69003015 D1 DE69003015 D1 DE 69003015D1 DE 90111365 A DE90111365 A DE 90111365A DE 69003015 A DE69003015 A DE 69003015A DE 69003015 D1 DE69003015 D1 DE 69003015D1
Authority
DE
Germany
Prior art keywords
daily
separate
dosage units
sequential
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE90111365A
Other languages
English (en)
Other versions
DE69003015T2 (de
DE69003015T4 (de
Inventor
Erkki Hirvonen
Ariel Gordin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Application granted granted Critical
Publication of DE69003015D1 publication Critical patent/DE69003015D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Plant Substances (AREA)
DE90111365A 1989-06-15 1990-06-15 Behandlung von Störungen in der Postmenopause. Expired - Fee Related DE69003015D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/366,424 US5043331A (en) 1989-06-15 1989-06-15 Treatment of postmenopausal disorders

Publications (1)

Publication Number Publication Date
DE69003015D1 true DE69003015D1 (de) 1993-10-07

Family

ID=23442937

Family Applications (2)

Application Number Title Priority Date Filing Date
DE90111365A Expired - Fee Related DE69003015D1 (de) 1989-06-15 1990-06-15 Behandlung von Störungen in der Postmenopause.
DE69003015T Expired - Lifetime DE69003015T4 (de) 1989-06-15 1990-06-15 Behandlung von Störungen in der Postmenopause.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69003015T Expired - Lifetime DE69003015T4 (de) 1989-06-15 1990-06-15 Behandlung von Störungen in der Postmenopause.

Country Status (10)

Country Link
US (1) US5043331A (de)
EP (1) EP0402950B1 (de)
JP (1) JPH0331213A (de)
AT (1) ATE93728T1 (de)
AU (1) AU635270B2 (de)
CA (1) CA2018818C (de)
DE (2) DE69003015D1 (de)
DK (1) DK0402950T3 (de)
IE (1) IE65864B1 (de)
NZ (1) NZ234051A (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
JP2722025B2 (ja) * 1991-07-19 1998-03-04 日本鋼管工事株式会社 光ファイバ融着部測定システム
DE4405590C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
US20030004145A1 (en) 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
DK1390040T3 (da) 2001-05-18 2007-04-23 Pantarhei Bioscience Bv Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
WO2002094279A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2278925T3 (es) 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
EP1453521B1 (de) * 2001-12-05 2013-09-04 Teva Women's Health, Inc. Orale kontrazeptiva zum vermeiden der schwangerschaft und verminderung von praemenstruellen symptomen
EP1340503A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Lösung Aerosol Formulierung von Estern von 3,17-dihydroxy Oestratrien-Derivaten zur Lungenverabreichung
BR0309032A (pt) * 2002-04-03 2005-02-01 Barr Lab Inc Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
AU2003274941A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
ATE340579T1 (de) 2002-06-11 2006-10-15 Pantarhei Bioscience Bv Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
AU2003253506A1 (en) 2002-07-12 2004-02-02 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
PT1556058E (pt) 2002-10-23 2008-03-20 Pantarhei Bioscience Bv Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
EP1624848A4 (de) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc Verfahren zur hormonbehandlung mit kontrazeptva-schemata mit verlängertem zyklus
BRPI0412493A (pt) * 2003-07-16 2006-10-17 Duramed Pharmaceuticals Inc métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
EP1673094A1 (de) * 2003-10-01 2006-06-28 Janssen Pharmaceutica N.V. Erweiterte triphasische kontrazeptive schemata
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
WO2008085038A2 (en) 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112019025914A2 (pt) * 2017-06-08 2020-06-30 Therapeuticsmd, Inc. composições farmacêuticas de estradiol para inserção vaginal e métodos
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet

Also Published As

Publication number Publication date
IE902164A1 (en) 1991-01-02
IE902164L (en) 1990-12-15
IE65864B1 (en) 1995-11-29
CA2018818C (en) 2001-01-16
DE69003015T2 (de) 1993-12-16
NZ234051A (en) 1991-09-25
CA2018818A1 (en) 1990-12-15
AU5587690A (en) 1990-12-20
AU635270B2 (en) 1993-03-18
JPH0331213A (ja) 1991-02-12
EP0402950A3 (de) 1991-02-06
EP0402950B1 (de) 1993-09-01
DK0402950T3 (da) 1993-10-25
US5043331A (en) 1991-08-27
ATE93728T1 (de) 1993-09-15
DE69003015T4 (de) 1994-05-26
EP0402950A2 (de) 1990-12-19

Similar Documents

Publication Publication Date Title
ATE93728T1 (de) Behandlung von stoerungen in der postmenopause.
NO914970D0 (no) Prostagen-bare kontraseptiv
DE69710896T2 (de) Progestogen-anti-progestogen therapien
NO955085L (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
ATE253365T1 (de) Estrensteroide als neurochemische initiatoren einer veränderung der hypothalmusfunktion beim menschen und verwandte pharmazeutische präparate
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
DE69724796D1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
DE69313534D1 (de) Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie
FR2713088B1 (fr) Utilisation de la vitamine B1 et ses dérivés pour la préparation d'un médicament destiné au traitement des affections dont les symptômes sont attribués aux désordres d'origine vasculaire.
PT94787A (pt) Processo de preparacao de composicoes farmaceuticas para administracao transdermica de corticosteroides e de compostos com actividade fisiologica semelhante
RU96124465A (ru) Способ лечения стойких дезадаптационных психовегетативных расстройств
TH27339A (th) ฮอร์โมนตัวใหม่ที่ใช้เป็นยาและประโยชน์ของมันในการรักษาภาวะขาดเอสโตเจน
ATE59776T1 (de) Pharmazeutische zusammensetzung und behandlung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee